SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike stock is facing sustained downward pressure driven by concerns over its turnaround strategy, slowing consumer demand, and intense sector competition, leading some investors to question the company's long-term growth trajectory. While the community is deeply divided between those labeling it a value trap destined for further declines and those aggressively accumulating shares at current levels to capture the dividend yield, active debate remains focused on whether management can effectively reclaim market share.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlist is trending as retail investors rally behind the company's strengthening patent portfolio and recent strategic settlement with Samsung, driving strong buying volume and optimism surrounding potential future deals with other major memory manufacturers. The community is focused on the long-term potential for institutional re-valuation and the pressure mounting on short sellers amidst significant, unresolved litigation catalysts.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms Inc. is facing renewed downward pressure as investors react to the start of a major federal trial involving allegations of addictive design features in its products, fueling widespread uncertainty. While some in the community view the persistent selling as a temporary reaction to recurring litigation risks and heavy AI-related capital expenditure, others are bracing for further volatility, leading to a polarized debate between those calling it a generational buying opportunity and those fearing a deeper structural decline.

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Charles Schwab is trending as investors react to a system outage that left many traders unable to access the platform, fueling intense frustration and calls for better reliability. While some users are pointing toward alternative brokerages, others are focused on the impact these frequent technical issues have on trading opportunities and account management.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is seeing intense social media chatter as the community debates its volatile price action, with some users highlighting insider selling concerns while others discuss the company's long-term viability. The discourse remains highly polarized, blending heavy political grievances against the former President with speculation regarding the company's financial future and its relationship to broader market trends.

Stellantis NV engages in the designing, engineering, manufacturing, distributing, and selling of vehicles and components. It offers its products under the Abarth, Alfa Romeo, Chrysler, Citroën, Dodge, DS Automobiles, Fiat, Jeep, Lancia, Maserati, Opel, Peugeot, Ram Trucks, Vauxhall, Free2move, and Leasys brands. The company was founded on April 1, 2014 and is headquartered in Hoofddorp, the Netherlands.

Stellantis N.V

Stellantis is attracting significant attention as investors weigh a aggressive turnaround strategy involving a massive multi-billion dollar investment to refresh its core brands like Jeep and Ram, while simultaneously navigating concerns over global inventory levels and intensifying competition from Chinese EV manufacturers. The community remains deeply divided, with some investors accumulating shares as a deep-value play on solid-state battery progress and potential margin recovery, while others express frustration over recent stock volatility, management's product roadmap, and broader sector pressures.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian continues to spark intense debate as investors weigh the company's aggressive production scaling of the R2 platform and promising high-margin software revenue against ongoing concerns over negative automotive gross margins and continued cash burn. The community remains deeply divided, with bulls highlighting the strategic long-term partnerships with Amazon and Uber alongside record institutional interest, while bears focus on weak share price performance and execution risks in a highly competitive EV market.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending as investors digest positive Phase 3 HARMONi-6 clinical data, which demonstrated a survival benefit for its lead candidate ivonescimab compared to current standards of care. Despite this, the stock is facing downward pressure from market-wide biotech volatility, concerns regarding China-based trial data, and community debate over the company's long-term capital requirements.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is trending due to the official launch of a strategic partnership with Apple for a new device leasing program, which is fueling investor enthusiasm despite recent volatility. Community discussions are centered on the potential for this high-profile collaboration to accelerate user growth and the upcoming court ruling regarding a major antitrust case against Google.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology is trending as investors weigh significant growth potential in sovereign AI infrastructure against concerns over share dilution and management's communication regarding earnings timelines. The community remains deeply divided, with some betting on a short squeeze fueled by strong revenue catalysts, while others express frustration over the stock's volatility and lack of clear financial transparency.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ODTX (Odyssey Therapeutics) 
Strong Nasdaq debut — opened ~$20, +11% vs $18 IPO price. 
Deal came in solid: 
$304M IPO (upsized) 
15.5M shares priced at top range 
Plus strategic placement from TPG Life Sciences 
Pipeline focus is pure immunology/autoimmune: 
OD-001 (RIPK2 inhibitor) for ulcerative colitis, including combo studies with Takeda Pharmaceutical Entyvio 
SLC15A4 program targeting lupus / B-cell diseases 
What stands out more is the leadership track record — prior exits tied to Eli Lilly and Company, Bristol Myers Squibb, Novartis, and prior biotech M&amp;A success stories. 
Classic biotech IPO structure: strong syndicate, heavy backing, long-dated clinical catalysts — not a quick flip, more of a pipeline story. 
 
Follow me    👉@ChipDistribution7 for real-time updates and everything. Let’s make moves!

StockTwits Web

Odyssey Therapeutics Inc

 (Odyssey Therapeutics) 
Strong Nasdaq debut — opened ~$20, +11% vs $18 IPO price. 
Deal came in solid: 
$304M IPO (upsized) 
15.5M shares priced at top range 
Plus strategic placement from TPG Life Sciences 
Pipeline focus is pure immunology/autoimmune: 
OD-001 (RIPK2 inhibitor) for ulcerative colitis, including combo studies with Takeda Pharmaceutical Entyvio 
SLC15A4 program targeting lupus / B-cell diseases 
What stands out more is the leadership track record — prior exits tied to Eli Lilly and Company, Bristol Myers Squibb, Novartis, and prior biotech M&A success stories. 
Classic biotech IPO structure: strong syndicate, heavy backing, long-dated clinical catalysts — not a quick flip, more of a pipeline story. 
 
Follow me    👉

 for real-time updates and everything. Let’s make moves!